Human disease
dry eye syndrome
Mondo defines it as: “A syndrome characterized by dryness of the cornea and conjunctiva. It is usually caused by a deficiency in tear production. Symptoms include a feeling of burning eyes and a possible foreign body presence in the eye.”
1 disease group in OMIA reaches this disease, through OMIA's own Mondo link or its OMIM numbers. The page shows the chain. It does not say whether an animal is a model of this disease.
Animal diseases
By natural-model score for this disease, highest first. The score says how complete and how well supported each chain is, by stated rules. How the score works.
| OMIA group | Name | Found by | Species | The chain reached | Score |
|---|---|---|---|---|---|
| 2393 | Keratoconjunctivitis sicca | The group's name | 1 | Human disease |
31.5
|
Human genes
Each human gene of these disease groups that Open Targets links to this disease.
Open Targets links none of these groups' human genes to this disease.
Drugs tested for this disease
Each ChEMBL drug that has been tested for this disease, and the human genes above it acts on, if any. Open Targets gives some drugs, such as most enzyme replacement therapies, no target gene.
| Drug | Acts on | Latest stage for this disease |
|---|---|---|
| Cyclosporine | None of these genes | Approved |
| Lifitegrast | None of these genes | Approved |
| Loteprednol Etabonate | None of these genes | Approved |
| Perfluorohexyloctane | None of these genes | Approved |
| Rebamipide | None of these genes | Approved |
| Arsenic | None of these genes | Phase 3 |
| Brm-421 | None of these genes | Phase 3 |
| Carboxymethylcellulose | None of these genes | Phase 3 |
| Carboxymethylcellulose Sodium | None of these genes | Phase 3 |
| Cholecalciferol | None of these genes | Phase 3 |
| Chondroitin Sulfate | None of these genes | Phase 3 |
| Cinhyaluronate Sodium | None of these genes | Phase 3 |
| Dexamethasone Phosphoric Acid | None of these genes | Phase 3 |
| Diquafosol | None of these genes | Phase 3 |
| Hyaluronic Acid | None of these genes | Phase 3 |
| Hydroxychloroquine | None of these genes | Phase 3 |
| Methylprednisolone | None of these genes | Phase 3 |
| Ozagrel | None of these genes | Phase 3 |
| Piclidenoson | None of these genes | Phase 3 |
| Pilocarpine | None of these genes | Phase 3 |
| Prednisolone | None of these genes | Phase 3 |
| Prednisone | None of these genes | Phase 3 |
| Reproxalap | None of these genes | Phase 3 |
| Rimexolone | None of these genes | Phase 3 |
| Tacrolimus Anhydrous | None of these genes | Phase 3 |
| Tanfanercept | None of these genes | Phase 3 |
| Tavilermide | None of these genes | Phase 3 |
| Timbetasin Acetate | None of these genes | Phase 3 |
| Tivanisiran | None of these genes | Phase 3 |
| Tivanisiran Sodium | None of these genes | Phase 3 |
| Varenicline | None of these genes | Phase 3 |
| Xanthan Gum | None of these genes | Phase 3 |
| Ecabet | None of these genes | Phase 2/3 |
| Trimix | None of these genes | Phase 2/3 |
| Voclosporin | None of these genes | Phase 2/3 |
| Acetylcysteine | None of these genes | Phase 2 |
| Betamethasone Phosphoric Acid | None of these genes | Phase 2 |
| Bromfenac | None of these genes | Phase 2 |
| Canakinumab | None of these genes | Phase 2 |
| Cenegermin | None of these genes | Phase 2 |
| Cis-Urocanic Acid | None of these genes | Phase 2 |
| Difluprednate | None of these genes | Phase 2 |
| Doxycycline Anhydrous | None of these genes | Phase 2 |
| Hypromellose | None of these genes | Phase 2 |
| Ketorolac | None of these genes | Phase 2 |
| Levocarnitine | None of these genes | Phase 2 |
| Licaminlimab | None of these genes | Phase 2 |
| Mapracorat | None of these genes | Phase 2 |
| (+)-Menthol | None of these genes | Phase 2 |
| Menthol | None of these genes | Phase 2 |
| Mycophenolic Acid | None of these genes | Phase 2 |
| Naltrexone | None of these genes | Phase 2 |
| Navamepent | None of these genes | Phase 2 |
| Nerve Growth Factor | None of these genes | Phase 2 |
| Pimecrolimus | None of these genes | Phase 2 |
| Progesterone | None of these genes | Phase 2 |
| Recoflavone | None of these genes | Phase 2 |
| Rivoglitazone | None of these genes | Phase 2 |
| Secukinumab | None of these genes | Phase 2 |
| Simpinicline | None of these genes | Phase 2 |
| Sirolimus | None of these genes | Phase 2 |
| Testosterone | None of these genes | Phase 2 |
| Thalidomide | None of these genes | Phase 2 |
| Thymosin | None of these genes | Phase 2 |
| Zucapsaicin | None of these genes | Phase 2 |
| Acoltremon | None of these genes | Phase 1/2 |
| Ambroxol | None of these genes | Phase 1/2 |
| Atorvastatin | None of these genes | Phase 1/2 |
| Botulinum Toxin Type A | None of these genes | Phase 1 |
| Isunakinra | None of these genes | Phase 1 |
| Ivermectin | None of these genes | Phase 1 |
| R-348 | None of these genes | Phase 1 |
| Spironolactone | None of these genes | Early phase 1 |
| Amlisimod | None of these genes | Unknown |
| Carbomer 910 | None of these genes | Unknown |
| Dexamethasone | None of these genes | Unknown |
| Dextran | None of these genes | Unknown |
| Glycerin | None of these genes | Unknown |
| Hydrocortisone | None of these genes | Unknown |
| Omega-3-Acid Ethyl Esters | None of these genes | Unknown |
| Omega-3 Fatty Acids | None of these genes | Unknown |
| Polyethylene Glycol | None of these genes | Unknown |
| Polysorbate 80 | None of these genes | Unknown |
| Propylene Glycol | None of these genes | Unknown |
| Rondaptivon Pegol | None of these genes | Unknown |
| Sodium Chloride | None of these genes | Unknown |
| Timbetasin | None of these genes | Unknown |
| Tobramycin | None of these genes | Unknown |
The drug data is ChEMBL's, under CC BY-SA 3.0, and came through Open Targets release 26.09.